J INTS BIO, Oral TKI 'JIN-A04', poster presentation of HER2 exon20 insertion mutation in NSCLC

SEOUL,South Korea,Feb. 7,2023 -- J INTS BIO announced that the preclinical results of "JIN-A04," a novel oral tyrosine kinase inhibitor (TKI) targeting HER2 Exon20 insertion mutation in NSCLC,will be presented at the upcoming 2023 American Cancer Research Association meeting in Orlando,U.S. from April 14to 19.

J INTS BIO CI

HER2 Exon20 insertion mutation accounts for 2-3% of NSCLC and there is currently no approved oral targeted therapy.

"JIN-A04" showed potent efficacy against HER2 Exon20 insertion mutant NSCLC cell lines,and in-vivo mouse models using HER2 Exon20 insertion mutant cell lines significant tumor regression was demonstrated.

J INTS BIO completed the application for designation of 'JIN-A04' as an orphan drug with the US FDA in August last year and said that the procedure for designation as an orphan drug is in progress. As a result,the company said,"If JIN-A04 is approved for designation as an orphan drug,it will be possible for it to be used in patients after the completion of Phase 1 and Phase 2 clinical trials." To this end,the company plans to submit an IND to the US and Korea in the first half of this year,allowing us to enter Phase 1 clinical study in the US and Korea simultaneously.

About J INTS BIO

J INTS BIO is a bio company specialized in developing innovative anti-cancer and orphan drugs to realize the goal of changing lives and improving health for patients around the world. J INTS BIO's teams have prior multi-year experience in multinational pharmaceutical companies and CROs and track records in medical,regulatory affairs,drug discovery and development.

About 'JIN-A04'

Novel oral TKI targeting NSCLC with HER2 Exon20 insertion mutation. 'JIN-A04' demonstrate potent in-vitro and in-vivo models and is expected to be a gamechanger in the cancer that currently have no approved oral targeted therapies.

View original content to download multimedia:https://www.prnewswire.com/news-releases/j-ints-bio-oral-tki-jin-a04-poster-presentation-of-her2-exon20-insertion-mutation-in-nsclc-301740200.html